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Membrane-bound human liver alkaline phosphatase olubilized by a non-ionic detergent, Nonidet P-40 
(NP-40), has the molecular mass of a tetramer. It can be converted to a dimeric form by treatment with 
a phosphatidylinositol phospholipase C (PI-PLC) obtained from Bacillus cereus. When human liver plasma 
membranes were directly treated with PI-PLC, the released alkaline phosphatase wasdimeric. Thus, phos- 
phatidylinositol may help maintain the tetrameric quaternary structure of alkaline phosphatase and aid its 
binding to human liver plasma membranes. 
Aikaline phosphatase; Liver (human); Plasma membrane; P~osphatidylinositol phospholipase C; 
Detergent -solubilized alkaline phosphatase 
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1. INTRODUCTION 
Alkaline phosphatase (orthophosphoric-mono- 
ester phosphohydrolase [alkaline optimum, EC 
3.1.3.1]) purified from human liver is a dimeric 
glycoprotein of A& 135000-186000 [1,2]. 
However, recent work in this laboratory has 
revealed alkaline phosphatase in a tetrameric form 
in its native, membrane-bound state [3]. Also, 
others have found the enzyme associated with PI in 
the membranes of various mammali~ tissues, 
having released the alkaline phosphatase from the 
membranes with purified PI-PLCs from bacterial 
sources [4,5]. The attachment of alkaline 
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phosphatase to the membrane may be due to a 
strong interaction, covalent or non-covalent, with 
the membrane’s PI [6,7], an attachment thought to 
apply to several other mammalian membrane- 
bound enzymes that can be released with bacterial 
PI-PLCs [5,8,9]. We now report the use of PI- 
PLC as a probe to study the nature of attachment 
of alkaline phosphatase to human liver plasma 
membranes and to study the relationship between 
the enzyme’s tetrameric and dimeric forms. 
2. EXPERIMENTAL 
Phospholipase C (Bacillus cereus) type III, 
NP-40, p-nitrophenylphosphate, and naphthol 
AS-MX phosphate were purchased from Sigma (St 
Louis, MO), ethylaminoethanol from Aldrich 
(Milwaukee, WI), mol~ul~-rn~s markers for 
electrophoresis from Pharmacia (Uppsala, 
Sweden), and 2.5-2770 polyacrylamide gradient 
gels from Isolab (Akron, OH). All other chemicals 
were reagent grade (Fisher Scientific, Fairlawn, 
NJ, USA). 
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Plasma membranes were isolated [3], and 
alkaline phosphatase was purified to homogeneity 
as judged by gel electrophoresis in SDS [lo]. PI- 
PLC was purified from a commercial preparation 
of nonspecific phospholipase C [I I]. Alkaline 
phosphatase was assayed in 1 ml of medium con- 
taining ~-nitrophenylphosphate (10 mmol/l) and 
ethylaminoethanol (1.0 mol/l), pH 10.3, at 30°C; 
the increase in absorbance at 404 nm was 
monitored with a spectrophotometer (Varian, 
model 2200). Enzyme activity (U) was expressed as 
rmol of p-nitrophenol released/min per 1, Protein 
concentrations were determined using a BCA pro- 
tein assay reagent (no.23225; Pierce, Rockfold, IL, 
USA). 
Aliquots of isolated plasma membranes 
(alkaline phosphatase activity = 600 U/l) suspend- 
ed in a buffer containing 50 mmol/l Tris, 10% 
(v/v) glycerol, pH 7.6, were incubated with equal 
volumes of PI-PLC in the same buffer at 30°C. 
Final PI-PLC concentrations were from Opglml 
(control) to 5.0~g/ml and incubation times were 
from 15 to 75 min. At each incubation time, an ali- 
quot of each sample was centrifuged at 95000 x g 
for 8 min; enzyme activity recovered from the 
supernatant fluid was expressed as a percentage of 
the activity in the uncentrifuged control. 
The molecular mass of alkaline phosphatase in 
each sample (250 U/l in 100 ~1) was determined by 
electrophoresis in gradient gels (2.5-27% 
polyacrylamide gradient) for 18 h at 150 V in a 
buffer containing (per liter) 0.09 mol Tris and 
0.08 mol borate, pH 8.4 [2]. The gels were stained 
in naphthol AS-MX phosphate (3 mg/ml) dis- 
solved in ethylaminoethanol 1.0 mol/l, pH 10.3. 
They were viewed under UV light until fluorescing 
band(s) of alkaline phosphatase became visible [2], 
then the markers were stained with Coomassie blue 
G-250 [3]. 
NP-40 was added to purified plasma membranes 
(600 U activity/l) suspended in 50 mmol/l Tris, 
10% (v/v) glycerol, pH 7.6, to give 1% (v/v) 
NP-40. Samples were mixed at 4°C for 1 h and 
then centrifuged for 15 min at 95000 x g. The 
supernatant fluid (containing the detergent- 
solubiliz~ enzyme) was divided into three ali- 
quots: to one aliquot (control) was added an equal 
amount of buffer (50 mmol/l Tris, 10% (v/v) 
glycerol, pH 7.6) containing no PI-PLC; to the 
other two was added an equal volume of PI-PLC 
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(in 50 mmol/l Tris, and 10% (v/v) glycerol, pH 
7.6) to give final PI-PLC concentrations of 5.0 pg 
and 57.4 @g/ml, respectively. NP-40 was added to 
all 3 incubation mixtures, to a final concentration 
of 6% (v/v). The samples were incubated at 30°C 
for 1 h and then applied to gradient gels. 
3, RESULTS AND DISCUSSION 
The amount of alkaline phosphatase released 
from the liver plasma membranes was propor- 
tional to the PI-PLC concentration and the dura- 
tion of treatment at a fixed PI-PLC concentration 
(fig-l). Inhibitors of proteolytic enzymes (PMSF, 
0.02010 (w/v); leupeptin, 1 Icmolfl; bestatin, 
0.23 mmol/l; and pepstatin A, 0.10 mmolll) did 
not inhibit the PI-PLC-mediated release of the en- 
zyme (not shown). The released enzyme had a 
molecular mass of 214 kDa, and thus was in- 
distinguishable from the ‘soluble’ alkaline 
phosphatase purified by our standard protocol. 
Also, PI-PLC converted detergent-solubilized 
tetrameric enzyme to dimers (fig.2), to a degree 
proportionate to the PI-PLC concentration. 
Bacterial PI-PLCs can solubilize membrane- 
bound ALP from various non-human mammalian 
tissues. This indicates that PI contributes to the en- 
zyme’s attachment on the plasma membrane [4,5]; 
a role applicable to the human liver enzyme, which 
can also be solubilized by a bacterial PI-PLC 1121. 
Alkaline phosphatase released from the human 
liver plasma membranes by PI-PLC was in the 
30 45 60 75 
Time ( mm ) 
Fig. 1. Solubilization of membrane-bound alkaline 
phosphatase by PI-PLC applied in the following 
concentrations (f&ml): 0, 0; A , 0.2; H , 1 .O; 0, 5.0. 
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Fig.2. Gradient gel electrophoresis of alkaline 
phosphatase r leased from plasma membranes by PI- 
PLC and the detergent-solub~lized enzyme treated with 
PI-PLC. Lanes: A, protein markers; B, purified liver 
alkaline phosphatase; C, alkaline phosphatase r leased 
from membranes by PI-PLC. Lanes D-F, 
NP-40-solubilized alkaline phosphatase; D, control, 
incubated without PI-PLC; E, incubated with PI-PLC 
(5.0 pg/ml); F, incubated with PI-PLC (57.4 pg/ml). 
dimeric, water-soluble form. It is highly unlikely 
that proteolytic activity was a cause of this release, 
in view of the lack of inhibition of this release by 
protease inhibitors. Conversion of the detergent- 
soluble tetrameric alkaline phosphatase to dimers 
by PI-PLC shows that PI may also have a role in 
maintaining the quaternary structure of this 
enzyme. 
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